Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.
Widmer
N
N
Gotta
V
V
Haouala
A
A
Decosterd
L A
LA
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001774:Blood Chemical Analysis / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000378:metabolism; D008991:Monitoring, Physiologic / Q000379:methods; D009994:Osmolar Concentration; D010349:Patient Compliance; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases